TELA Bio 배당금 및 환매

배당금 기준 확인 0/6

TELA Bio 배당금을 지급한 기록이 없습니다.

주요 정보

n/a

배당 수익률

-0.1%

환매 수익률

총 주주 수익률	-0.1%
미래 배당 수익률	n/a
배당금 성장	n/a
다음 배당금 지급일	n/a
전 배당일	n/a
주당 배당금	n/a
지급 비율	n/a

최근 배당금 및 환매 업데이트

업데이트 없음

Recent updates

Even With A 27% Surge, Cautious Investors Are Not Rewarding TELA Bio, Inc.'s (NASDAQ:TELA) Performance Completely

Nov 09

Not Many Are Piling Into TELA Bio, Inc. (NASDAQ:TELA) Stock Yet As It Plummets 33%

Aug 19

Does TELA Bio (NASDAQ:TELA) Have A Healthy Balance Sheet?

Jul 03

Shareholders May Be More Conservative With TELA Bio, Inc.'s (NASDAQ:TELA) CEO Compensation For Now

May 29

TELA Bio, Inc. (NASDAQ:TELA) Soars 31% But It's A Story Of Risk Vs Reward

May 23

Earnings Update: TELA Bio, Inc. (NASDAQ:TELA) Just Reported Its Annual Results And Analysts Are Updating Their Forecasts

Mar 24

TELA Bio: Tailwinds In Hernia Repair Market And Promising Clinical Data To Drive Accelerating Adoption

Oct 02

Tela Bio prices $32M common stock offering

Aug 16

Is TELA Bio (NASDAQ:TELA) Using Debt Sensibly?

May 12

TELA Bio - Follow Up With Management

Jan 14

Our First Look At TELA Bio

Nov 04

TELA Bio Plugging Away

Oct 25

TELA Bio (TELA) Investor Presentation - Slideshow

May 26

결제의 안정성과 성장

배당금 데이터 가져오기

안정적인 배당: 과거에 TELA 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.

배당금 증가: TELA 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.

시장 대비 배당 수익률

TELA Bio 시장 대비 배당 수익률

TELA 배당 수익률은 시장과 어떻게 비교되나요?
세그먼트	배당 수익률
회사 (TELA)	n/a
시장 하위 25% (US)	1.4%
시장 상위 25% (US)	4.3%
업계 평균 (Medical Equipment)	1.7%
애널리스트 예측 (TELA) (최대 3년)	n/a

주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 TELA 의 배당 수익률을 평가할 수 없습니다.

고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 TELA 의 배당 수익률을 평가할 수 없습니다.

주주에 대한 수익 배당금

수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 TELA 의 지급 비율을 계산하기에는 데이터가 부족합니다.

주주에 대한 현금 배당금

현금 흐름 범위: TELA 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.

TELA Bio 배당금 및 환매

배당금 기준 확인 0/6

주요 정보

최근 배당금 및 환매 업데이트

Recent updates

Even With A 27% Surge, Cautious Investors Are Not Rewarding TELA Bio, Inc.'s (NASDAQ:TELA) Performance Completely

TELA Bio, Inc. has completed a Follow-on Equity Offering in the amount of $40.04942 million.

TELA Bio, Inc. has completed a Follow-on Equity Offering in the amount of $40.04942 million.

TELA Bio, Inc. to Report Q3, 2024 Results on Nov 07, 2024

Not Many Are Piling Into TELA Bio, Inc. (NASDAQ:TELA) Stock Yet As It Plummets 33%

TELA Bio, Inc. to Report Q2, 2024 Results on Aug 12, 2024

TELA Bio, Inc.(NasdaqGM:TELA) dropped from Russell Small Cap Completeness Index

Does TELA Bio (NASDAQ:TELA) Have A Healthy Balance Sheet?

TELA Bio, Inc. Appoints Jeffrey Blizard to its Board of Directors

Shareholders May Be More Conservative With TELA Bio, Inc.'s (NASDAQ:TELA) CEO Compensation For Now

TELA Bio, Inc. (NASDAQ:TELA) Soars 31% But It's A Story Of Risk Vs Reward

TELA Bio, Inc. Appoints Greg Firestone as Chief Commercial Officer

TELA Bio, Inc. Provides Revenue Guidance for the Year 2024

First quarter 2024 earnings released: US$0.23 loss per share (vs US$0.63 loss in 1Q 2023)

TELA Bio, Inc. to Report Q1, 2024 Results on May 09, 2024

TELA Bio, Inc., Annual General Meeting, Jun 04, 2024

TELA Bio, Inc. Announces U.S. Commercial Launch of Robotic-Compatible OviTex IHR

Earnings Update: TELA Bio, Inc. (NASDAQ:TELA) Just Reported Its Annual Results And Analysts Are Updating Their Forecasts

TELA Bio, Inc. Announces U.S. Commercial Launch of LIQUIFIX

Full year 2023 earnings released: US$2.04 loss per share (vs US$2.72 loss in FY 2022)

Many Still Looking Away From TELA Bio, Inc. (NASDAQ:TELA)

TELA Bio, Inc. to Report Q4, 2023 Results on Mar 21, 2024

Consensus EPS estimates fall by 215%

TELA Bio, Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

Price target decreased by 18% to US$14.40

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

TELA Bio, Inc. to Report Q3, 2023 Results on Nov 09, 2023

TELA Bio (NASDAQ:TELA) Has Debt But No Earnings; Should You Worry?

John Nosenzo Resigns as Member of the Board of Directors of TELA Bio, Inc

TELA Bio, Inc. Announces U.S. Commercial Launch of OviTex PRS Long-Term Resorbable for Plastic and Reconstructive Surgery

Consensus EPS estimates upgraded to US$0.57 loss

Second quarter 2023 earnings: EPS exceeds analyst expectations

TELA Bio, Inc. Reaffirms Revenue Guidance for Full Year 2023

Getting In Cheap On TELA Bio, Inc. (NASDAQ:TELA) Might Be Difficult

TELA Bio, Inc. to Report Q2, 2023 Results on Aug 09, 2023

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Tela Bio, Inc. Reaffirms Earnings Guidance for the Full Year 2023

Insufficient new directors

Consensus EPS estimates fall by 13%, revenue upgraded

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

TELA Bio Announces U.S. Commercial Launch of NIVIS Fibrillar Collagen Pack

Price target decreased to US$17.40

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased to US$17.40

TELA Bio, Inc. Provides Revenue Guidance for the Full Year 2022

TELA Bio, Inc. to Report Q3, 2022 Results on Nov 09, 2022

TELA Bio, Inc. Announces Publication of 24-Month Bravo Study Results Demonstrating Benefits of Ovitex(R) Reinforced Tissue Matrix in Hernia Repair

TELA Bio: Tailwinds In Hernia Repair Market And Promising Clinical Data To Drive Accelerating Adoption

Consensus forecasts updated

TELA Bio, Inc. has completed a Follow-on Equity Offering in the amount of $32 million.

Tela Bio prices $32M common stock offering

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

TELA Bio, Inc. Provides Revenue Guidance for the Full Year 2022

Tela Bio, Inc. Highlights Results from BRAVO and ReBAR Studies on the Benefits of OviTex® Reinforced Tissue Matrix in Hernia Repairs

TELA Bio, Inc. to Report Q2, 2022 Results on Aug 10, 2022

CFO & COO recently bought US$83k worth of stock

TELA Bio, Inc. Provides Revenue Guidance for the Fiscal Year 2022

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Is TELA Bio (NASDAQ:TELA) Using Debt Sensibly?

TELA Bio, Inc. Announces Revenue Guidance for the Full Year 2022

TELA Bio, Inc., Annual General Meeting, Jun 01, 2022

TELA Bio, Inc. Appoints Taylor Ocasio as General Counsel

TELA Bio, Inc. Announces U.S. Commercial Launch of SiteGuard™ No Rinse Antimicrobial Solution

TELA Bio - Follow Up With Management

High number of new directors

Third quarter 2021 earnings released: US$0.57 loss per share (vs US$0.53 loss in 3Q 2020)

Our First Look At TELA Bio

TELA Bio Plugging Away

TELA Bio® Announces New Data on Use of OviTex in a Range of Hernia Repair Applications, Including Novel ReBAR (Reinforced Biologic Augmented Repair) Technique

Second quarter 2021 earnings released: US$0.57 loss per share (vs US$0.53 loss in 2Q 2020)

TELA Bio, Inc. Provides Earnings Guidance for the Full Year 2021

High number of new directors

TELA Bio, Inc.(NasdaqGM:TELA) dropped from Russell 3000E Index

Independent Director Adele Oliva has left the company

Chief Financial Officer Nora Brennan has left the company